TKIs (tyrosine kinase inhibitors) such as Gleevec, Sprycel, Tasigna and Bosulif have been shown to be highly effective in blocking the leukemia signals that drive the proliferation of white blood cells (WBC) in CML.
CML was once considered a death sentence, with people typically living only a few years after being diagnosed. But have TKI medications, such as Gleevec, Sprycel, Tasigna or Bosulif, actually made a difference?
A number of environmental factors have been implicated in the development of CML. Recent studies have suggested that chronic, heavy smokers do have a greater risk of developing chronic myelogenous leukemia.